A growing number of prescription medicines could soon be sold without a doctor’s approval, as US regulators explore expanding the list of drugs available over the counter. Supporters say the change will save patients time and money. Yet a closer look at how this shift has played out with other medicines suggests the picture is far more complicated, and the risks involved deserve far more attention than they are currently getting.

Why the Push for Easier Access Is Growing

For decades, moving a drug from prescription to over the counter status has been rare and carefully controlled. Roughly three dozen such switches have happened in the United States since 2001, most involving everyday complaints like allergies, heartburn and headaches. Each one went through a lengthy review process designed to confirm that patients could safely diagnose and treat themselves without a clinician’s guidance.

That caution exists for good reason. When a prescriber is involved, patients benefit from a trained professional checking symptoms, confirming the right medicine and dose, and watching for warning signs along the way. Pharmacists add another layer of protection, offering counselling and catching potential problems before they cause harm. Remove that oversight, and the responsibility for getting it right shifts almost entirely onto the patient and the product label.

The Hidden Costs Behind Convenience

One of the strongest arguments for wider over the counter access is affordability. Skipping a doctor’s visit certainly saves time, and for some conditions that convenience is genuinely valuable. But the savings are not guaranteed. Over the counter medicines are typically not covered by insurance, meaning patients pay the full retail price out of pocket. Manufacturer assistance programmes, which help many patients afford prescription drugs, generally stop working once a medicine loses its prescription status.

This matters most for the people who can least afford it. Families already struggling with tight budgets may end up paying more overall once insurance support disappears, even if the sticker price looks lower at first glance. There is also a real risk that patients delay proper treatment, self diagnosing conditions that actually need clinical attention, or missing warning symptoms that overlap with more serious illness.

Common Painkillers Show the Over the Counter Medicine Risks Clearly

Everyday over the counter pain relievers illustrate these dangers well. Acetaminophen, found in countless household products, remains a leading cause of acute liver failure linked to accidental overdose. Anti inflammatory drugs such as ibuprofen and naproxen carry their own dangers, including stomach bleeding, ulcers, kidney injury and cardiovascular problems when used at high doses or over long periods. These are medicines millions of people already trust and use safely every day. Their track record shows precisely why removing a prescription requirement does not remove danger, it simply relocates where that danger sits.

In one widely reported case, a major manufacturer resolved more than two hundred liver injury lawsuits and paid tens of millions of dollars to settle claims that its labelling had misrepresented product safety. Incidents like this are a reminder that a label alone, however well written, cannot replace the judgement of a trained clinician standing beside a patient.

Reducing Over the Counter Medicine Risks Requires More Than Convenience

None of this means convenience and accessibility are unworthy goals. Reducing unnecessary barriers to care matters, particularly for people who face real difficulty reaching a doctor. But convenience built on weaker safeguards is not the same as genuine progress. True patient protection depends on prevention focused education long before a product ever reaches a shop shelf, alongside clear labelling, properly resourced pharmacist counselling and robust monitoring once a medicine is in wider circulation.

Patients deserve information and support that helps them avoid harm altogether, not simply a faster route to a product with unfamiliar risks attached. As policymakers weigh further changes to how medicines reach the public, the priority should remain firmly on equipping people to make genuinely informed, safe decisions rather than assuming that easier access alone solves the affordability problem.

Source: jamanetwork